X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (102) 102
index medicus (77) 77
male (67) 67
female (66) 66
aged (64) 64
hematology (61) 61
multiple myeloma (58) 58
middle aged (57) 57
multiple myeloma - drug therapy (56) 56
treatment outcome (46) 46
antineoplastic combined chemotherapy protocols - therapeutic use (42) 42
bortezomib (39) 39
oncology (38) 38
adult (33) 33
thalidomide (33) 33
disease-free survival (30) 30
thalidomide - administration & dosage (29) 29
multiple myeloma - mortality (27) 27
stem-cell transplantation (27) 27
aged, 80 and over (26) 26
dexamethasone (26) 26
therapy (24) 24
chemotherapy (23) 23
survival (22) 22
lenalidomide (21) 21
melphalan - administration & dosage (21) 21
antineoplastic combined chemotherapy protocols - adverse effects (19) 19
retrospective studies (19) 19
dexamethasone - administration & dosage (18) 18
analysis (17) 17
survival analysis (16) 16
transplantation (16) 16
care and treatment (15) 15
multiple myeloma - pathology (15) 15
multiple myeloma - therapy (15) 15
survival rate (15) 15
thalidomide - adverse effects (15) 15
thalidomide - analogs & derivatives (15) 15
elderly-patients (14) 14
hematology, oncology and palliative medicine (14) 14
melphalan (14) 14
prognosis (14) 14
prospective studies (13) 13
risk factors (13) 13
abridged index medicus (12) 12
antineoplastic agents - therapeutic use (12) 12
cancer (12) 12
thalidomide - therapeutic use (12) 12
combination (11) 11
follow-up studies (11) 11
kaplan-meier estimate (11) 11
prednisone (11) 11
prednisone - administration & dosage (11) 11
stem cells (11) 11
transplantation, autologous (11) 11
clinical trials (10) 10
initial treatment (10) 10
medical research (10) 10
pegylated liposomal doxorubicin (10) 10
recurrence (10) 10
adolescent (9) 9
antineoplastic combined chemotherapy protocols - administration & dosage (9) 9
autologous transplantation (9) 9
boronic acids - administration & dosage (9) 9
clinical trials as topic (9) 9
cyclophosphamide (9) 9
doxorubicin - administration & dosage (9) 9
hematopoietic stem cell transplantation (9) 9
leukemia (9) 9
multiple-myeloma (9) 9
pyrazines - administration & dosage (9) 9
remission induction (9) 9
stem cell transplantation (9) 9
bortezomib-melphalan-prednisone (8) 8
carfilzomib (8) 8
diagnosis (8) 8
lenalidomide plus dexamethasone (8) 8
maintenance (8) 8
maintenance therapy (8) 8
melphalan - adverse effects (8) 8
mortality (8) 8
multiple myeloma - complications (8) 8
patients (8) 8
salvage therapy (8) 8
bone marrow (7) 7
dexamethasone - therapeutic use (7) 7
doxorubicin - analogs & derivatives (7) 7
drug therapy (7) 7
medicine, experimental (7) 7
multiple myeloma - diagnosis (7) 7
neoplasm staging (7) 7
pharmacology & pharmacy (7) 7
phase-ii (7) 7
prednisone - adverse effects (7) 7
research (7) 7
time factors (7) 7
trial (7) 7
antineoplastic agents - administration & dosage (6) 6
antineoplastic agents - adverse effects (6) 6
boronic acids - adverse effects (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 27 - 38
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9758, pp. 2075 - 2085
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1617 - 1629
Summary Background High-dose melphalan plus autologous stem-cell transplantation (ASCT) is the standard approach in transplant-eligible patients with newly... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | ONCOLOGY | CONSOLIDATION THERAPY | INITIAL TREATMENT | THALIDOMIDE | BORTEZOMIB | INDUCTION | STEM-CELL TRANSPLANTATION | DEXAMETHASONE COMBINATION | ELDERLY-PATIENTS | MELPHALAN | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Transplantation, Autologous | Melphalan - therapeutic use | Hematopoietic Stem Cell Transplantation - mortality | Cyclophosphamide - therapeutic use | Thalidomide - analogs & derivatives | Multiple Myeloma - therapy | Time Factors | Hematopoietic Stem Cell Transplantation - adverse effects | Female | Maintenance Chemotherapy | Chemotherapy, Adjuvant | Thalidomide - adverse effects | Prednisone - adverse effects | Multiple Myeloma - diagnosis | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Disease Progression | Disease-Free Survival | Czech Republic | Dexamethasone - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Italy | Aged | Thalidomide - therapeutic use | Australia | Prednisone - therapeutic use | Medical colleges | Cyclophosphamide | Care and treatment | Chemotherapy | Dexamethasone | Multiple myeloma | Stem cells | Product development | Prednisone | Transplantation | Cancer
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 10, pp. 895 - 905
In patients 65 or younger with multiple myeloma, high-dose consolidation therapy was associated with longer survival and more myelotoxicity than... 
MEDICINE, GENERAL & INTERNAL | PREDNISONE | PLUS DEXAMETHASONE | INDUCTION THERAPY | LENALIDOMIDE | INITIAL TREATMENT | RANDOMIZED CONTROLLED-TRIAL | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | MELPHALAN | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Transplantation, Autologous | Consolidation Chemotherapy | Antineoplastic Agents, Alkylating - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Multiple Myeloma - therapy | Melphalan - adverse effects | Adult | Maintenance Chemotherapy | Neutropenia - chemically induced | Thalidomide - adverse effects | Prednisone - administration & dosage | Prednisone - adverse effects | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Aged | Antineoplastic Agents, Alkylating - adverse effects | Stem Cell Transplantation - adverse effects | Complications and side effects | Care and treatment | Patient outcomes | Multiple myeloma | Stem cells | Transplantation | Research | Health aspects | Autografts | Chemotherapy | Cell survival | Transplants & implants | Melphalan | Stem cell transplantation | Death | Prednisone | Drug dosages | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2010, Volume 28, Issue 34, pp. 5101 - 5109
Journal Article
Future Oncology, ISSN 1479-6694, 02/2018, Volume 14, Issue 4, pp. 319 - 329
Monoclonal antibodies (mAb) represent a new frontier to treat newly diagnosed and relapsed-refractory multiple myeloma (MM). Elotuzumab, an mAb targeted SLAM7... 
elotuzumab | SLAMF7 | multiple myeloma | lenalidomide | monoclonal antibody | NATURAL-KILLER-CELLS | DENDRITIC CELLS | PROGRESSION-FREE SURVIVAL | MONOCLONAL-ANTIBODY | OPEN-LABEL | PHASE-2 | COMBINATION | ONCOLOGY | IMMUNOTHERAPY | LOW-DOSE DEXAMETHASONE
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2014, Volume 32, Issue 7, pp. 634 - 640
Journal Article